ROBOSENSE
RoboSense announced a strategic partnership with Horizon Robotics, a global pioneer in edge AI computing platforms. The two partners will mobilize their respective technological capacity and mass production experience to roll out in-depth cooperation focusing on advanced driver assistance systems (ADAS), autonomous driving, robotics, new intelligent transportation infrastructure and other applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211223005234/en/
Leveraging its leading smart LiDAR software and hardware technologies, RoboSense will join hands with Horizon Robotics to promote the large-scale commercialization of all segments of intelligent connected vehicle.
According to the partnership agreement, based on RoboSense’s second generation smart solid-state LiDAR RS-LiDAR-M1 (hereinafter referred to as "M1") and Horizon Robotics’ Journey 3 and Journey 5 automotive smart chips, the two companies will collaborate on the development and adaptation of integrated perception solutions for high-level autonomous driving pre-installed mass production. In the future, the partners will mobilize their respective advantageous industry resources to jointly promote the all-round standardized implementation of the domestic intelligent connected transportation industry.
Dr. Chunxin Qiu, founder and CEO of RoboSense:
" This strategic partnership will form a greater joint force and empower the two companies to create more visionary intelligent driving product solutions for the industry, to jointly build a prosperous ecology of the vehicle intelligence industry and advance the development of the intelligent connected transportation industry. "
Dr. Kai Yu, founder and CEO of Horizon Robotics:
" Through this strategic partnership, the two companies will fully complement each other with respective advantageous resources, jointly explore cutting-edge technologies and promote the mass production and large-scale implementation of pioneering intelligent driving solutions of the industry, leveraging technological innovation to build a safer and better smart mobility experience for the future. "
RoboSense is currently the only company in China to realize the automotive-grade domestic mass production of pre-installed LiDAR. Its second generation smart solid-state LiDAR, M1, has obtained pre-installed fixed-point project orders from multiple brands including GAC AION, WM Motor, ZEEKR, Lotus Cars, Inceptio and Zhito, covering models including passenger cars and commercial vehicles.
Horizon Robotics is a global leader in edge AI computing platforms based on the forward-looking concept of software and hardware integration As the only company in China to realize the automotive-grade domestic mass production of pre-installed AI chips, Horizon Robotics has reached intended partnership on priority mass production delivery with multiple car manufacturers including SAIC Motor, GWM, JAC Group, Changan Auto and BYD.
RoboSense and Horizon Robotics have a profound partnership history. The two companies announced intended partnership as early as 2019, and have been discussing and exploring innovations and integration solutions of vehicle intelligence technology, laying a solid foundation for the implementation of long-term and stable partnership achievements in the future.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211223005234/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom